Patents by Inventor Jerome W. Kosmeder, II

Jerome W. Kosmeder, II has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170212019
    Abstract: Disclosed embodiments concern a composition comprising DAB chromogen, and/or derivative thereof, a stabilizer, and polymer capable of preventing or reducing DAB precipitation relative to a composition that does not comprise the polymer. Also disclosed herein is a method for using the disclosed composition and embodiments of a kit.
    Type: Application
    Filed: April 10, 2017
    Publication date: July 27, 2017
    Inventors: Christopher Bieniarz, Brian D. Kelly, Jerome W. Kosmeder, II, Eric J. May, Larry Morrison
  • Patent number: 9435795
    Abstract: This disclosure relates to compositions that enhance the deposition of detectable moieties on tissue samples, methods utilizing these compositions and kits including these compositions. The compositions include a deposition enhancer having a formula where R1, R2, R3, and R4 are independently selected from aliphatic, aryl, halogen, a heteroatom-containing moiety, and hydrogen; R1 and/or R3 can be bound to R2 to form a fused, aromatic ring system; R5 is selected from a heteroatom-containing moiety; A is selected from, a carbon atom, a heteroatom, other than sulfur, and any combination thereof; n is 1-5, an enzyme, a specific binding moiety and a detectable moiety.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: September 6, 2016
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Eric J. May, Adrian E. Murillo, Jerome W. Kosmeder, II
  • Patent number: 9315789
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: April 19, 2016
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Jennifer Wong, Mark Lefever, Jerome W. Kosmeder, II, Julia Ashworth-Sharpe, Casey A. Kernag
  • Publication number: 20150024405
    Abstract: This disclosure relates to compositions that enhance the deposition of detectable moieties on tissue samples, methods utilizing these compositions and kits including these compositions. The compositions include a deposition enhancer having a formula where R1, R2, R3, and R4 are independently selected from aliphatic, aryl, halogen, a heteroatom-containing moiety, and hydrogen; R1 and/or R3 can be bound to R2 to form a fused, aromatic ring system; R5 is selected from a heteroatom-containing moiety; A is selected from, a carbon atom, a heteroatom, other than sulfur, and any combination thereof; n is 1-5, an enzyme, a specific binding moiety and a detectable moiety.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Applicant: Ventana Medical Systems, Inc.
    Inventors: Eric J. May, Adrian E. Murillo, Jerome W. Kosmeder, II
  • Publication number: 20140323336
    Abstract: A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 30, 2014
    Applicant: Ventana Medical Systems, Inc.
    Inventors: Jerome W. Kosmeder, II, Mark Lefever, Donald Johnson, Michael Farrell, Zhanna Zhilina, Christopher Bieniarz
  • Publication number: 20140147906
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Application
    Filed: January 2, 2014
    Publication date: May 29, 2014
    Applicant: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Jennifer Wong, Mark Lefever, Jerome W. Kosmeder, II, Julia Ashworth-Sharpe, Casey A. Kernag
  • Patent number: 8658389
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: February 25, 2014
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Jennifer Wong, Mark Lefever, Jerome W. Kosmeder, II, Julia Ashworth-Sharpe, Casey A. Kernag
  • Publication number: 20130260379
    Abstract: Disclosed herein are embodiments of a signaling conjugate, embodiments of a method of using the signaling conjugates, and embodiments of a kit comprising the signaling conjugate. The disclosed signaling conjugate comprises a latent reactive moiety and a chromogenic moiety that may further comprise a linker suitable for coupling the latent reactive moiety to the chromogenic moiety. The signaling conjugate may be used to detect one or more targets in a biological sample and are capable of being covalently deposited directly on or proximally to the target. Particular disclosed embodiments of the method of using the signaling conjugate comprise multiplexing methods.
    Type: Application
    Filed: March 22, 2013
    Publication date: October 3, 2013
    Applicant: Ventana Medical Systems, Inc.
    Inventors: Nelson Alexander, William Day, Jerome W. Kosmeder, II, Mark Lefever, Larry Morrison, Anne M. Pedata, Stacey Stanislaw
  • Patent number: 7091195
    Abstract: A composition and method of preventing or inhibiting tumor growth and, more particularly, of treating a malignant tumor, using prodrugs of plant-derived compounds and derivatives is disclosed. In the method, a composition containing betulinic acid or a betulinic acid derivative is administered in a prodrug form to release betulinic acid or a betulinic acid derivative in vivo at the tumor site.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: August 15, 2006
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: John M. Pezzuto, Jerome W. Kosmeder, II, Ze-Qi Xu, Nian E. Zhou, Miriam Elaine Goldsmith
  • Patent number: 6569842
    Abstract: A composition and method of preventing or inhibiting tumor growth and, more particularly, of treating a malignant tumor, using prodrugs of plant-derived compounds and derivatives is disclosed. In the method, a composition containing betulinic acid or a betulinic acid derivative is administered in a prodrug form to release betulinic acid or a betulinic acid derivative in vivo at the tumor site.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: May 27, 2003
    Assignee: Board of Trustees of the University of Illinois, The
    Inventors: John M. Pezzuto, Jerome W. Kosmeder, II, Ze-Qi Xu, Nian En Zhou, Miriam Elaine Goldsmith
  • Patent number: 6046231
    Abstract: A composition and method of cancer chemoprevention is disclosed. The composition and method utilize 4'-bromoflavone as a cancer chemo-preventative agent in mammals, including humans.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: April 4, 2000
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Jerome W. Kosmeder, II, Robert M. Moriarty, John M. Pezzuto, Lynda Li Song, Richard C. Moon